Prostate Cancer Management: A Comprehensive Approach to Treatment

Prostate Cancer Management: A Comprehensive Approach to Treatment

Introduction:
Prostate cancer is a leading cause of cancer-related deaths among men worldwide. As medical advancements continue to evolve, so does the understanding and treatment options for this disease. In this article, we will explore the guidelines and considerations for managing prostate cancer, including the role of PSA levels, imaging techniques, and treatment selection in metastatic hormone-sensitive prostate cancer (mHSPC).

PSA Levels as a Prognostic Indicator:
The Prostate-Specific Antigen (PSA) level has long been used as a marker for prostate cancer progression. Studies have shown that patients who are treated before their PSA levels rise above 0.5 ng/mL have a higher chance of achieving an undetectable PSA level and being progression-free for up to 5 years. This highlights the importance of early detection and intervention in managing prostate cancer [824, 825-828, 748].

The Role of Imaging Techniques:
Imaging techniques play a crucial role in detecting and monitoring prostate cancer, especially in cases of biochemical recurrence (BCR) after prostatectomy. Recent studies have shown the effectiveness of 68Ga-PSMA PET in identifying recurrence in patients with BCR and PSA levels below 0.5 ng/mL. This imaging technique has demonstrated higher sensitivity compared to choline PET/CT, particularly for PSA levels below 1 ng/mL [325, 806, 807].

Understanding the Prognostic Factors:
Various prognostic factors have been identified in patients with BCR after radical prostatectomy (RP) or radiation therapy (RT). For patients with BCR after RP, positive surgical margins, high RP specimen pathological ISUP grade, high pT category, short PSA doubling time (PSA-DT), and high pre-sRT PSA are associated with distant metastatic recurrence. Similarly, high RP specimen pathological ISUP grade, short interval to biochemical failure, and short PSA-DT are significant prognostic factors for prostate-cancer-specific mortality and overall mortality [790, 791].

Management Options for pN+ Disease:
Patients with pN+ disease after an extended lymph node dissection (eLND) have different management options. Based on nodal involvement characteristics, three options can be considered: adjuvant androgen deprivation therapy (ADT), adjuvant ADT with additional radiotherapy, or observation (expectant management) for patients with less than 2 nodes with microscopic involvement, a PSA below 0.1 ng/mL, and no extranodal extension.

Treatment Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC):
When selecting treatment options for mHSPC, considering molecular status can be crucial. Studies have shown that docetaxel, a chemotherapy drug, does not provide an overall survival (OS) benefit in patients with the Basal subtype. However, patients with the Luminal B subtype showed improved OS when treated with docetaxel in addition to ADT. This highlights the importance of molecular profiling in treatment decision-making [ASCO GU 2020].

Actionable Advice:

1. Offer early PSA testing to well-informed men at an elevated risk of prostate cancer, such as those carrying BRCA2 mutations aged above 40 years.
2. Consider the availability of PSMA PET/CT or alternative imaging techniques like fluciclovine PET/CT or choline PET/CT when the PSA level is above 1 ng/mL and treatment decisions may be influenced by imaging results.
3. Monitor serum calcium levels and provide calcium and vitamin D supplementation when prescribing denosumab or bisphosphonates to prevent complications.

Conclusion:
Prostate cancer management requires a comprehensive approach that considers various factors such as PSA levels, imaging techniques, and molecular profiling. Early detection, appropriate imaging, and informed treatment decisions based on individual characteristics are essential for improving patient outcomes. By incorporating the latest guidelines and understanding the evolving therapeutic landscape, healthcare professionals can provide optimal care to patients with prostate cancer.